There is no Stanford longevity protocol. Not one Stanford has published, anyway.
The phrase circulates online attached to a bundle of ideas — time-restricted feeding, NAD+ precursors, autophagy — and it borrows the university's name to do work the university itself hasn't done. Underneath the label, though, sit three genuine research threads. Real laboratories study all three. Real Nobel Prizes have been awarded in two of the fields involved. And real marketing has run far ahead of both.
Strip the branding away and longevity research keeps circling the same three questions. When should you eat? How do cells turn food into energy? And how do cells clean up after themselves? Time-restricted feeding takes the first question. NAD+ biology takes the second. Autophagy — the cell's internal recycling system — takes the third. Notice something: none of the three is really about a product. Each is about a signal. How cells sense energy, and what changes when the signal changes.
When you eat is a variable too
Time-restricted feeding is a form of intermittent fasting with a simple rule: all calories land inside a daily window — commonly eight to ten hours — and the rest of the day is a fast. The most studied version in human trials is 16:8, sixteen hours without food and eight hours in which to eat. No special foods. No proprietary anything. Just a clock.
Two Nobel-recognized fields explain why researchers take the clock seriously. From autophagy research comes the finding that nutrient deprivation switches on the cell's recycling programs. From circadian biology — the field behind the 2017 Nobel Prize to Hall, Rosbash, and Young, who worked out the molecular clockwork — comes the fact that metabolism itself runs on a schedule. Insulin sensitivity is generally higher earlier in the day. The body's machinery is not the same at 9 a.m. and 9 p.m., even if the meal is.
That is why early time-restricted feeding draws particular interest. In that version, the eating window sits in the morning and afternoon rather than stretching into the night — calories arrive while insulin sensitivity runs higher, and the fast that follows is long enough to matter to the pathways Ohsumi mapped. The combination is elegant: the circadian work says metabolism is timed, the autophagy work says scarcity is a signal, and an early window leans on both at once — the same clockwork that governs sleep and circadian rhythm. Elegant is not the same as proven.
And the trials? They find roughly what intermittent fasting trials find generally. Improvements in weight. Improvements in markers like blood sugar and blood pressure. Numbers broadly comparable to what standard calorie restriction achieves — which suggests the window may work largely by helping people eat less, not by magic. Some smaller trials of early time-restricted feeding have reported additional metabolic benefits. Promising. But the evidence base is still modest, and researchers describe the findings as suggestive rather than conclusive. No human trial has demonstrated lifespan extension from time-restricted feeding. None could, quickly: such a study would take decades. Anyone claiming otherwise is selling something.
Nor is fasting for everyone. Pregnant or breastfeeding individuals shouldn't adopt a fasting pattern without medical supervision. Neither should people with a history of disordered eating, those with diabetes on glucose-lowering drugs, or frail older adults. A schedule that is low-risk for a healthy adult can be genuinely hazardous for someone whose blood sugar is managed by medication. The window is simple. Bodies aren't.
The molecule that fades
Nicotinamide adenine dinucleotide — NAD+ — is a coenzyme found in every living cell, sitting at the center of the chemical reactions that convert food into usable energy. It also serves as a substrate for enzymes involved in DNA repair and cellular stress responses: raw material for the cell's maintenance crews. Multiple lines of research have shown NAD+ levels decline with age across tissues. That single fact explains most of the excitement. If a molecule this central fades as we get older, restoring it sounds like an obvious target. It has become one.
The restoration strategy drawing the most attention involves precursors — compounds the body can convert into NAD+. The two most studied are nicotinamide mononucleotide, NMN, and nicotinamide riboside, NR. Both now have name recognition far beyond the literature. What the literature actually says is narrower, and more interesting. Both compounds have been tested in human clinical trials, which confirm the narrow point: NMN and NR can raise NAD+-related markers in blood. The precursor gets in. The level goes up. That part works.
Why, then, doesn't a rising blood marker settle the question? Because a marker is a measurement, not an outcome. The outcomes are the human ones — muscle function, cognition, years of healthy life — and those are exactly what the trials have not yet measured. A compound can do precisely what it was designed to do chemically and still fail to change what a person can do or how long they stay well.
What the trials have not established is everything people actually care about. Whether raising NAD+ translates into improved muscle function: not shown. Better cognition: not shown. Longer life: not shown. The biomarker moves. The clinical payoff remains unproven. That gap — between a mechanism that responds and an outcome that matters — is the defining feature of the NAD+ story right now. The biology is real, and major academic centers study it. But the distance from "levels decline with age" to "supplementation extends healthy life" is precisely the distance clinical science has not yet crossed. A field can be promising and unproven at the same time. This one is.
One recycling system underneath
Autophagy ties the threads together. As Yoshinori Ohsumi's Nobel-winning work established, cells under nutrient scarcity ramp up their internal recycling — breaking down damaged proteins and worn-out organelles to liberate energy and building blocks. A cell in lean times doesn't just endure; it tidies, salvages, reuses. Now look back at the other two topics. Time-restricted feeding is, in effect, a daily, mild nutrient-scarcity signal — a scheduled lean time. And NAD+-dependent enzymes participate in the stress-response pathways that govern how cells handle exactly that kind of scarcity. Three topics, one system: how cells sense energy availability, and how they respond to it.
Framed that way, the research program asks a clean question: can nudging those sensing pathways support healthier aging? It is a question laboratories can actually work on — in model organisms, in controlled trials, over years — and a very different thing from a shopping list. The same biology that makes the question worth asking also sets the pace of the answer, because sensing pathways are connected to everything else a cell does. Pull one lever and others move. That is why the field moves carefully, and why its language stays hedged even when the mechanism looks beautiful. Viewed as products to buy today, though, the same threads outrun the data: a coherent mechanism makes a beautiful story, and a beautiful story sells capsules. The mechanism being real is exactly why the story sounds plausible — and exactly why it needs trial discipline before it deserves belief. Plausibility is not evidence. In this field, it isn't even close.
What the serious labs do differently
Contrast the supplement marketing with how actual longevity science operates. The credible research centers — university aging-biology programs, institutes devoted to the biology of aging — work primarily in model organisms. They run controlled trials with pre-registered outcomes: the questions written down before the experiment starts, so the goalposts can't quietly move afterward. They publish negative results alongside positive ones. Their timelines are measured in years, their language hedged, because biology is complicated and they know it. None of that is a flaw. It is what the work looks like when the point is to find out, rather than to sell.
Institutions with serious aging-biology programs behave accordingly. Stanford's Center on Longevity, one frequently cited example, focuses less on any single protocol and more on broader determinants of healthy aging: physical activity, nutrition quality, sleep and circadian rhythm, social connection, and the management of chronic disease risk. Its published work emphasizes modifiable behaviors with large human evidence bases — preserving strength and muscle with age among them — rather than any fasting schedule or supplement. The contrast instructs: marketing promises transformation from a single lever, while academic research keeps returning to the unglamorous fundamentals, which explain most of the variance in who ages well. Time-restricted feeding and NAD+ biology are legitimate subplots in that larger story, alongside work on stress regulation and the nervous system — but subplots. The main narrative remains movement, sleep, diet quality, and not smoking.
A practical filter helps readers navigate the space: be skeptical of any "protocol" attributed to an institution that the institution itself has not published. Universities publish papers, not secret regimens. When a real finding emerges — as with Ohsumi's autophagy work, or the circadian clock discoveries — it arrives with named researchers, peer review, and, in those cases, a Nobel committee's attention. Not a sales page. If a claim can't survive that filter, it was packaging, not science.
So where does this leave someone curious about the science? Eating within a consistent daily window, especially earlier in the day, is a low-risk pattern with modest supportive evidence for metabolic health — best undertaken with attention to overall nutrition, not as a license to eat poorly inside it. NAD+ biology is a genuine research frontier, but the precursors remain investigational, and none has been shown to extend human healthspan. Autophagy is real, Nobel-certified cell biology, and its triggers — fasting and exercise among them — are worth understanding, though manipulating it deliberately in humans remains experimental. Aging is the product of dozens of interacting processes, and any single lever, however elegant, is unlikely to be the whole story. The most defensible strategy remains the least exciting one — the fundamentals, practiced consistently, while science does its slower work.
Protocols sell certainty; the population data sells a warning. People are living longer again, but spending more of those years ill is the statistic every fasting and supplement regimen has to answer. The interventions with the dullest branding keep performing best in that comparison — Zone 2 cardio and VO2 max benchmarks predict the healthspan outcomes that exotic protocols promise, with a fraction of the caveats.
Disclaimer: This article is for informational purposes only and is not medical advice. Do not start supplements or fasting regimens without consulting a qualified healthcare professional.
Sources
- Scientific American — "Nobel in Physiology or Medicine to Yoshinori Ohsumi for Autophagy Discoveries": scientificamerican.com
- Quanta Magazine — "Nobel Prize Awarded for Biological Clock Discoveries": Quantamagazine.org
